title: Effect of recombinant interferon gamma and interleukin-2 and of a monoclonal antibody against interferon gamma on the rat immune response against heart allografts.
abstract: We studied the effect of rat rec-IFN-gamma, human rec-IL-2, and an IgG1 monoclonal antibody (DB1) directed against rat IFN-gamma on allograft survival in the rat in various experimental conditions. The DB1 monoclonal antibody did not prolong heart allograft survival in the (LEW/BN)F1 to LEW combination, even when used at high doses (2 mg/rat x 9 days). Rec-IFN-gamma induced major histocompatibility antigen expression in vivo, but its administration had no effect on the graft survival either of untreated LEW recipients of (LEW x BN)F1 heart allografts or of donor blood-transfused LEW recipients. In addition, rec-IFN-gamma alone had no effect on graft survival in cyclosporine-treated rats. In contrast, rec-IL-2 shortened heart allograft survival both in untreated and in cyclosporine-treated recipients. Rec-IFN-gamma partially reversed the effects of rec-IL-2 in cyclosporine-treated rats. The data suggest that in vivo administration of IFN-gamma in allograft recipients may have a suppressor effect, in addition to the postulated augmenting effect on the immune response by increasing MHC antigen expression.
authors.affiliation: INSERM U.211 (Unité de Recherche sur les Effecteurs Lymphocytaires T) Nantes, France.
authors.forename: J
authors.initials: J
authors.lastname: Paineau
authors.forename: C
authors.initials: C
authors.lastname: Priestley
authors.forename: J
authors.initials: J
authors.lastname: Fabre
authors.forename: S
authors.initials: S
authors.lastname: Chevalier
authors.forename: P
authors.initials: P
authors.lastname: van der Meide
authors.forename: H
authors.initials: H
authors.lastname: Schellekens
authors.forename: Y
authors.initials: Y
authors.lastname: Jacques
authors.forename: J P
authors.initials: JP
authors.lastname: Soulillou
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003524:Cyclosporins / Q000627:therapeutic use; D006084:Graft Rejection / Q000276:immunology*; D006085:Graft Survival / Q000276:immunology*; D016027:Heart Transplantation / Q000276:immunology*; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D008297:Male; D051381:Rats; D011917:Rats, Inbred Lew; D011994:Recombinant Proteins / Q000627:therapeutic use; D014184:Transplantation, Homologous
chemical_list: D000911:Antibodies, Monoclonal; D003524:Cyclosporins; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; D007376:Interleukin-2; D011994:Recombinant Proteins; D007371:Interferon-gamma